Diabetes Dialogue: Omnipod 5 and Medtronic 780G for Type 2 Diabetes Medical Ethics Unpacked: GLP-1 Allocation and Challenges of Equitable Access Diabetes Dialogue: Understanding Semaglutide (Ozempic) in CKD and T2D Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Therapeutics ...
Type 2 diabetes can cause nerve damage, blindness, heart attack and stroke, among many other issues. “With Type 2 diabetes, your body can no longer make or use insulin, the hormone which helps the body regulate glucose levels,” Dr. Sheri Colberg, a professor of human movement sciences ...
However, gender difference may be particularly pronounced for impaired fasting glucose, as the American Diabetes Association (ADA) and World Health Organization (WHO) have adopted different cutoff points (fasting plasma glucose: 5.6 to <7.0 mmol/l and 6.1 to <7.0 mmol/l, respectively). Recently,...
the American Diabetes Association (ADA)-recommended daily allowance of protein is approximately 0.8 g/kg body weight per day, for people with non-dialysis-dependent diabetic kidney disease. This level has shown to slow GFR decline compared with higher levels of protein intake. The ADA doe...
According to the ADA, a person can be diagnosed with diabetes if they meet one of these criteria: They have a fasting blood glucose level greater than or equal to 126 mg/dL. They have a blood glucose level greater than or equal to 200 mg/dL two hours after they drink a special sugar...
Type 2 diabetes mellitus consists of an array of dysfunctions characterized by hyperglycemia and resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagon secretion. Poorly controlled type 2 diabetes is associated with an array of...
According to new guidelines from the American Diabetes Association (ADA), doctors should consider adding either a GLP-1 receptor agonist or SGLT-2 inhibitor if blood sugar levels are still too high despite metformin or a person has an increased risk of cardiovascular or kidney disease. The ADA ...
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy A consensus statement from the ADA and the EASD. Diabetologia 2006 ; 49: 1711–1721.Nathan D, Buse JB, Davidson MB, Management of hyperglycaemia in type 2 diabetes: A consensus ...
Data from the AWARD-PEDS study presented at ADA 2022 suggest once-weekly dulaglutide could improve glycemic control in youth with type 2 diabetes, with a safety profile consistent with that observed in adult patients. Silva Arslanian, MD Results of a new study suggest use of...
Collaborative efforts, such as those by the American Diabetes Association (ADA) and KDIGO, have produced evidence-based guidelines to improve clinical outcomes for individuals with DM and CKD13,33. Despite several studies on the prevalence of and risk factors for CKD among diabetic patients in ...